January 10, 2014
The third workshop on orphan product designation and grants jointly organized by the European Medicines Agency (EMA), the US Food and Drug Administration (FDA) and, for the first time, the Japanese Ministry of Health, Labour and Welfare (MHLW) and Pharmaceuticals and Medical Devices Agency (PMDA) will be held on March 10, 2014, at the EMA (London, United Kingdom). Registration is now open.
The aim of this workshop is to provide information to companies and academics on the EMA, FDA and MHLW-PMDA systems for orphan medicine designation, and on the grant programs available for the development of orphan medicines for the treatment of rare diseases.
There is no registration fee for attending the workshop. Participants need to register online for both morning and afternoon sessions. Registration is limited to 150 participants for the morning session.